Mont. AG sues Purdue Pharma for deceptive marketing for opioids | Novo's once-weekly drug approved by FDA | Antimicrobial claim for Sonoma's atopic dermatitis drug OK'd by FDA
ADVERTISEMENT
December 6, 2017
FDLI SmartBrief
News for the food and drug law community
SIGN UP ⋅   FORWARD
Drugs & Biologics
Mont. AG sues Purdue Pharma for deceptive marketing for opioids
Mont. AG sues Purdue Pharma for deceptive marketing for opioids
(Joe Raedle/Getty Images)
Purdue Pharma minimized the risks of OxyContin in marketing campaigns in an effort to boost prescriptions, according to a lawsuit filed by Montana Attorney General Tim Fox.
KTVH-TV (Helena, Mont.) (12/4) 
Email
 
Novo's once-weekly drug approved by FDA
Novo Nordisk's once-weekly Ozempic, or semaglutide injection, was approved by the FDA for use in adult patients with type 2 diabetes as an adjunct to exercise and diet for the improvement of glycemic control.
Seeking Alpha (free registration) (12/5) 
Email
Antimicrobial claim for Sonoma's atopic dermatitis drug OK'd by FDA
The FDA granted Sonoma Pharmaceuticals approval to include an antimicrobial claim for its Alevicyn SG Antipruritic Spray Gel, a treatment for atopic dermatitis or eczema. Data showing effectiveness of the gel against clinically relevant organisms was included in the approval.
Seeking Alpha (free registration) (12/5) 
Email
Sanofi terminates development of C. diff vaccine
Sanofi terminated development of its Clostridium difficile vaccine based on an Independent Data Monitoring Committee's assessment that the vaccine had a low probability of success after looking at interim data from a late-stage study.
FiercePharma (12/4),  Seeking Alpha (free registration) (12/1) 
Email
Global Focus
Novartis' AML drug turned down by NICE
The National Institute for Health and Care Excellence recommended against National Health Service and Cancer Drugs Fund use of Novartis' Rydapt, or midostaurin, as a treatment for patients with FLT3-mutated acute myeloid leukemia. The regulator did not consider the drug cost-effective and was uncertain of Rydapt's effectiveness in people older than age 60 because a clinical trial did not include that age group.
PharmaTimes (U.K.) (12/6) 
Email
NICE rejects Roche's giant cell arteritis therapy
Roche Holding's Roactemra, or tocilizumab, was turned down by the National Institute for Health and Care Excellence for funding by the National Health Service as a therapy for patients with giant cell arteritis. The institute did not find enough evidence showing how long patients would need to take Roactemra and what its long-term benefits would be and ruled that the drug's benefit did not meet cost-effectiveness standards.
PharmaTimes (U.K.) (12/6) 
Email
Food & Dietary Supplements
Supplement manufacturer settles charges over misbranded products
Supplement manufacturer settles charges over misbranded products
(Mladen Antonov/AFP/Getty Images)
Health Research Laboratories has settled with the state of Maine and the Federal Trade Commission on charges that it misbranded its brain supplement NeuroPlus and dietary supplement BioTherepex. The FTC said the supplements were marketed as treatments that could reverse memory loss, prevent dementia, treat arthritis and lead to weight loss, and the company used direct-mail brochures featuring quotes from nonexistent consumers, doctors and, in one case, a false clinical study to back up the claims.
FDAnews (12/6) 
Email
 
Medical Devices
Abbott: Global implantations of St. Jude's Nanostim device remains halted
The global halt of implants of the Nanostim leadless pacemaker, manufactured by Abbott unit St. Jude Medical, remains in place after Abbott received reports about the detachment of the device's docking button, but there have been no serious injuries. The company recommended continued following of patients and said retrieval may be done only if the docking button is intact as shown by X-rays and if the procedure can be executed per usage instructions.
MassDevice (Boston) (12/5) 
Email
FDA clears Brainlab's MR contrast analysis software
Brainlab's Contrast Clearance Analysis software, which is intended for providing more insight into post-treatment tumor characteristics, was granted 510(k) clearance by the FDA. The software allows for MR image analysis to differentiate efficient contrast clearance regions from regions with contrast accumulation in most patients with cranial tumors.
AuntMinnie (free registration) (12/6) 
Email
Second Sight announces release of retinal prosthesis system in Iran
Second Sight Medical's Argus II retinal prosthesis system was introduced in Iran through the company's exclusive distribution partner, Arshia Gostar Darman. Two patients in the country have undergone implantation of the system, which uses electrical stimulation to induce visual perception in patients with retinitis pigmentosa.
MassDevice (Boston) (12/5) 
Email
Food and Drug Law Institute Highlights
FDLI 2018 Annual Conference: Exploring Advanced Topics in Food and Drug Law
FDLI 2018 Annual Conference: Exploring Advanced Topics in Food and Drug Law
May 3-4 | Washington, D.C.
The premier conference for the food and drug law community, the FDLI Annual Conference addresses every product category regulated by the FDA. The two-day event will bring together industry experts to cover the latest legal, regulatory and policy issues. Learn more.
Email
 
Update Magazine -- Japan: A Better Environment
Update Magazine -- Japan: A Better Environment
In this article, Chia-Feng Lu (Baker McKenzie) examines the Japanese government's efforts to revitalize its life sciences industry by attracting more clinical development activities and facilitating the discovery and development of novel therapies. Read online.
Email
 
JOBS
powered by
Associate Manager Quality Compliance
ALTRIA - Richmond, VA
  
  
Each day is the scholar of yesterday.
Publilius Syrus,
writer
Email
  
  
Learn more about FDLI:
About | Programs | Resources | Engage | Career
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Jobs Contact  -  jobhelp@smartbrief.com
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information